Ceftizoxime
Ceftizoxime is a third-generation cephalosporin available for parenteral administration. Unlike other third-generation cephalosporins, the whole C-3 side chain in ceftizoxime has been removed to prevent deactivation by hydrolytic enzymes. It rather resembles cefotaxime in its properties, but is not subject to metabolism. It was removed from the US Market in 2007.
Clinical data | |
---|---|
Trade names | Cefizox |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a684043 |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.210.846 |
Chemical and physical data | |
Formula | C13H13N5O5S2 |
Molar mass | 383.40 g·mol−1 |
Synthesis
Injectable third generation cephalosporin antibiotic related to cefotaxime, q.v. Exhibits broad spectrum activity and resistance to β-lactamase hydrolysis.
gollark: For language features you can use stuff like Babel (or TypeScript) to compile your shiny new code to ES5/6/whatever is supported by your target browsers.
gollark: The majority of the web platform™ works okay on recent browser things.
gollark: Most useful and widely-used web APIs run fine on anything newer than IE 11.
gollark: No, only if you use stupid cutting-edge stuff.
gollark: It's a good thing, though.
References
- T. Takaya et al., DE 2810922; eidem, U.S. Patent 4,427,674 (1978, 1984 both to Fujisawa).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.